The rationale is that this molecule is able to decrease hypoxia in the TME and is, therefore, able to re-sensitize melanoma tumors to anti-PD1 therapy in patients who have progressed on previous anti-PD1 therapy alone or in combination with anti-CTLA4 therapy [92]. Here, CTLA4 is linked to melanoma.